• Two animal models were assessed: hyperestrogenic and hypoestrogenic rats.
Introduction
Prolactin secretion is largely regulated by dopamine, but serotonergic neurons also play a role in neuroendocrine regulation of prolactin secretion. Serotonin (5-hydroxytryptamine, 5-HT) and 5-hydroxytryptophan (5-HTP) may increase prolactin secretion both in humans and in diverse animal models [5, 27, 28] under different physiological conditions, such as lactation and pregnancy.
Serotonergic receptors such as 5-HT1A, 5-HT2A and 5HT2C have been described in several studies as modulating prolactin release [1, 9, 12, 14] . However, controversial results have been reported. Some evidence in rodents indicates that the 5-HT2 receptor is involved in prolactin regulation [8, 16, 19] . In contrast, other studies report that the 5-HT1A subtype also participates in prolactin release [9, 19, 23] , a finding contested by others [4, 25] .
Regarding studies in humans, while some authors have reported that 5-HT1A receptors play a role in the control of prolactin secretion [18, 20] others point out that both 5-HT1A and 5-HT2A/2C receptors are required for prolactin secretion [12, 13] . Estrogen has also been recognized as being involved in the role of serotonergic pathways in prolactin release [15] , and evidence suggests that estradiol exerts an influence on 5-HT1A mRNA expression in limbic brain regions [17] and modulates serotonin levels and receptor numbers [2] .
We have previously shown that administering estradiol to animals treated with p-chlorophenylalanine (pCPA), an inhibitor of 5-HT synthesis, increases prolactin levels as compared with those observed in sham/normoestrogenic or ovariectomized/hypoestrogenic pCPA-treated rats [10] . Therefore, the present study aims to assess whether estradiol may modulate the serotonergic influence on prolactin secretion though 5-HT1A and 5-HT2A/2C receptors in rats under different conditions of estrogen treatment.
Materials and methods

Animals
Eighty-four female Wistar rats, 65-80 days old, weighing 180-220 g, were housed six to a cage under controlled temperature conditions (22 ± 4 • C) and a 12/12 h light-dark cycle with free access to standard certified rodent chow and tap water. All procedures performed on the rats were in compliance with the EC Directive 2010/63/EU on the protection of animals used for scientific purposes. The use of animals was reviewed and approved by the Research Ethics Committee, Federal University of Rio Grande do Sul Basic Health Sciences Institute.
Experimental procedures
All animals were subjected to bilateral ovariectomy (OVX) under anesthesia. At 5 days post-surgery, animals were randomly assigned to receive 300 g per week of estradiol benzoate (Benzoginoestril, Sarsa-São Paulo, Brazil), or sunflower oil vehicle (hyperestrogenic and hypoestrogenic animals, respectively) for 2 weeks, as previously reported [24] . In all experiments, the animals were killed 2 weeks after the first estradiol benzoate or vehicle injection. Animals were killed between 9 and 11 a.m. by decapitation. Trunk blood samples were collected from all animals and serum was harvested and stored at −20 • C until measurement of prolactin levels by a double-antibody radioimmunoassay. Drug administration was carried out during the last days of vehicle or estrogen treatment, between 8 and 11 a.m., as described below.
Experiment 1: Effect of serotonin receptor agonist MK-212 on the 5-HT2A/5-HT2C receptor subtypes
In the last 4 days before the end of the 2-week vehicle or estradiol treatment period, animals were also injected once daily with normal saline solution (0.9% NaCl) or 6-chloro-2-(1-piperazinyl)pyrazine (MK-212, Merck Institute for Therapeutic Research, West Point, PA, USA), subcutaneously, dissolved in 0.9% NaCl at a dose of 10 mg/kg/day. Animals were killed by decapitation 24 h after the end of the 2-week period.
Experiment 2. Effects of serotonin receptor agonist 8-OH-DPAT and antagonist pindolol on the 5-HT1A receptor subtype
On the last day of the 2-week period of vehicle or estradiol administration, part of the animals received 8-hydroxy-2-(di-Npropylamine)tetralin (8-OH-DPAT, Sigma Chemical Co., St. Louis, MO, USA), dissolved in 0.9% NaCl, by intraperitoneal injection, as a single 1 mg/kg dose 30 min before decapitation. The dose was determined on the basis of previous studies [4, 19] . 1 . Effect of MK-212 (10 mg/kg/day for 4 days), on prolactin levels. Hyperestrogenic females (E2 + saline, n = 9; E2 + MK-212, n = 9) were treated for 2 weeks with 300 g per week of estradiol benzoate. Hypoestrogenic females were administered saline (OVX + saline, n = 9) or MK-212 (OVX + MK-212, n = 8). Results are expressed as median and 25-75% interquartile range (lower and upper limit of the box); maximum and minimum values are shown by the limits of vertical lines. *p < 0.05; **p < 0.01 compared to control group (OVX + saline).
The other half of the group received pindolol (Visken ® , Sandoz, São Paulo, Brazil), dissolved in 0.9% NaCl, by subcutaneous injection, as a single 5 mg/kg dose 60 min before decapitation [21, 22] . Prolactin levels were compared among the groups of hypo-and hyperestrogenic animals under distinct drug treatments.
Prolactin assay
Prolactin levels (ng/mL) were measured by a double-antibody radioimmunoassay with reagents supplied by the National Hormone and Pituitary Program, U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA). Prolactin was radioiodinated by the chloramine-T method as described elsewhere [24] . NIDDK rat prolactin RP-3 was used as the standard. Assay sensitivity was 4 ng/mL and the intra-and interassay coefficients of variation were 8.6% and 12%, respectively.
Statistical analysis
Prolactin values for each group are expressed as median and interquartile range. Statistical analysis was performed by the Mann-Whitney U test. All analyses were performed in the GraphPadPrism 5 software environment (GraphPad Software, Inc., La Jolla, CA, USA). Differences were considered significant if the probability of error was less than 5%. Fig. 1 shows that prolactin levels were significantly higher in estradiol-treated ovariectomized rats (n = 9) than in vehicletreated animals (n = 9). MK-212 significantly increased prolactin concentrations in both hypoestrogenic (n = 8) (p < 0.05) and hyperestrogenic (n = 9) (p < 0.01) females as compared with controls. Other one animal died at the experimentation period. Fig. 2 shows the effects of the administration of 8-OH-DPAT to hyperestrogenic (n = 8) and hypoestrogenic animals (n = 8). Although prolactin concentrations were higher in hyperestrogenic females (n = 8) compared to hypoestrogenic animals (n = 8), treatment with 8-OH-DPAT did not alter prolactin levels as compared with saline control. Similar results were obtained with the administration of pindolol: although prolactin concentrations were higher in hyperestrogenic (n = 7) than in hypoestrogenic animals (n = 4), pindolol treatment did not change prolactin levels as compared with saline control. Other seven animals could not be used for experiments or died at the experimentation period.
Results
Effect of serotonin receptor agonist MK-212 on the 5-HT2A/5-HT2C receptor subtypes
Effects of serotonin receptor agonist 8-OH-DPAT and antagonist pindolol on the 5-HT1A receptor subtype
Discussion
In the present study, we tested whether estradiol can modulate serotonergic effects on prolactin secretion by acting directly on serotonergic receptors. Thus, the experiments were designed to identify whether the 5-HT2A/2C or 5-HT1A receptors subtypes were involved in this mechanism. In this sense, treatment with the serotonin receptor agonist MK-212 increased prolactin levels both in hyper-and hypoestrogenic females. Moreover, estradiol was found to strongly increase prolactin release when administered with this 5-HT2A/2C agonist [2] . These results suggest that the 5-HT2A receptor subtype is involved in prolactin secretion, as reported in a previous study carried out in turkeys [6] . However, while the present results suggest the 5-HT2C receptor subtype may also be involved in the regulation of prolactin secretion, a definitive role for this receptor can only be confirmed after testing the administration of new specific 5-HT2C antagonists [26] in combination with dose-response curves for estrogen administration to ovariectomized rats.
Studying a hypoestrogenic animal model, Flügge et al. [7] administrated DPAT, a 5-HT1A receptor agonist, to ovariectomized rats. The authors found that, in estradiol-treated females, both the number and affinity of 5-HT1A receptors were increased in the ventral medial nucleus in comparison with rats not administered estradiol. In contrast, in the present study, despite the increase in prolactin levels observed due to estradiol treatment, no effect was found on prolactin levels with the administration of DPAT or of the 5-HT1A antagonist pindolol. A previous study has reported that DPAT could promote a brief increase in prolactin levels in male rats [4] . Another study [1] showed that treatment with DPAT was efficient in increasing prolactin levels in prepubertal male rats. However, the experimental conditions of these studies using male animals, as well the doses of DPAT administered, differ from those of the present study; this could explain, at least in part, the contrasting results.
Concerning pindolol treatment, no differences in prolactin levels were found either in hyper-or in hypoestrogenic females. Few studies have assessed the interaction between 5-HT1A receptors, prolactin levels, and estrogenic status. In turn, using the same dose as described in the present study, a previous investigation found that pindolol antagonized the antidepressant effect of indorenate [11] . Evidence suggests that high-dose administration of pindolol in humans may augment antidepressant response [3] . Therefore, the absence of response to DPAT and pindolol treatment observed in the present study suggests that involvement of 5-HT1A receptors in estradiol-induced prolactin release is unlikely.
Conclusions
The present findings suggest that 5-HT2A/2C receptors are involved in prolactin release through serotonergic pathways in female animals, especially in the setting of a hyperestrogenic state. Further studies are needed to better define the interaction of the 5-HT2A/2C receptor subtypes, prolactin secretion, and the ovarian cycle during antidepressant treatment.
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